Masitinib Improves ALS Patients’ Functioning, Clinical Trial Results Show
Masitinib met its main Phase 2 and 3 clinical trial goal of improving the functioning of amyotrophic lateral sclerosis (ALS) patients, according to its maker, AB Science SA. The randomized, double-blind AB10015 (NCT02588677) trial compared the effectiveness and safety of a combination of masitinib and riluzole with a combination of…